Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de fase 2 de Ianalumabe (VAY736) em pacientes com trombocitopenia imune primária (PTI) previamente tratados com pelo menos duas linhas de terapias

19 de outubro de 2026 atualizado por: Novartis Pharmaceuticals

Um estudo de fase 2 para avaliar a eficácia e a segurança de Ianalumab (VAY736) em pacientes com trombocitopenia imune primária (PTI) previamente tratados com pelo menos um corticosteróide e um agonista do receptor de trombopoietina (TPO-RA)

The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.

Visão geral do estudo

Status

Ativo, não recrutando

Intervenção / Tratamento

Descrição detalhada

This is a phase 2, open-label, single-arm study to evaluate the efficacy, safety and tolerability of ianalumab in participants with primary ITP (platelet count <30 G/L at screening) previously treated with at least a corticosteroid and a TPO-RA.

The study consists of the screening period, the primary endpoint assessment period, the follow-up period. The screening period will last for up to 14 days prior to the first dose of ianalumab. All eligible participants will be treated with the same dose of ianalumab and will complete the primary endpoint assessment period. After completion of the primary endpoint assessment period, all participants will continue in safety monitoring and those with a platelet count ≥30 G/L in absence of a new line of ITP therapy and rescue therapy will also continue in efficacy monitoring. The trial includes an option to offer a second course of ianalumab treatment to participants who achieved confirmed response during the initial course of ianalumab and later lost response to explore the benefit of the second course of treatment. The study will end once all participants have completed 24 months of safety follow-up since their last dose of ianalumab (including the optional second course of ianalumab treatment),or discontinued the study earlier.

Tipo de estudo

Intervencional

Inscrição (Real)

41

Estágio

  • Fase 2

Acesso expandido

Disponível fora do ensaio clínico. Consulte registro de acesso expandido.

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Giessen, Alemanha, 35392
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Alemanha, 01307
        • Novartis Investigative Site
    • Thuringia
      • Jena, Thuringia, Alemanha, 07740
        • Novartis Investigative Site
      • CABA, Argentina, C1181ACH
        • Novartis Investigative Site
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Austrália, 2605
        • Novartis Investigative Site
    • Victoria
      • Melbourne, Victoria, Austrália, 3004
        • Novartis Investigative Site
      • Beijing, China, 100730
        • Novartis Investigative Site
      • Jinan, China, 250012
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Novartis Investigative Site
      • Seoul, Coréia do Sul, 06591
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Espanha, 08003
        • Novartis Investigative Site
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Estados Unidos, 02215
        • Beth Israel Deaconess Med Center
      • Toulouse, França, 31059
        • Novartis Investigative Site
    • TO
      • Torino, TO, Itália, 10126
        • Novartis Investigative Site
      • Johor Bahru, Malásia, 80100
        • Novartis Investigative Site
      • Katowice, Polônia, 40-519
        • Novartis Investigative Site
      • Glasgow, Reino Unido, G31 2ER
        • Novartis Investigative Site
      • London, Reino Unido, W12 0HS
        • Novartis Investigative Site
      • Izmir, Turquia (Türkiye), 35100
        • Novartis Investigative Site
      • Kocaeli, Turquia (Türkiye), 41380
        • Novartis Investigative Site
    • Efeler
      • Aydin, Efeler, Turquia (Türkiye), 09100
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turquia (Türkiye), 34098
        • Novartis Investigative Site
    • Merkez
      • Edirne, Merkez, Turquia (Türkiye), 22030
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 100 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Signed informed consent obtained prior to participation in the study.

  • Male or female participants aged 18 years and older on the day of signing informed consent.

  • Confirmed diagnosis of primary ITP.

    • Prior treatment with at least a corticosteroid (±IVIG) and a TPO-RA:
    • Prior additional therapies are allowed; the corticosteroid or the TPO-RA do not need to be the last treatment.
    • Prior response to IVIG/anti-D or a corticosteroid (platelet count ≥50 G/L) that was not maintained.
  • At last ITP treatment, loss of response, insufficient response, no response or intolerance.

  • Platelet count <30 G/L and assessed as needing treatment (per physician's discretion) at screening. If concomitant ITP medication is clinically indicated, the platelet assessment showing a value <30 G/L must be performed after at least 14 days on a stable dose of a corticosteroid or/and a TPO-RA (less than 10% variation from current dose) and continue stable thereafter.

Key exclusion criteria:

  • Diagnosis of secondary thrombocytopenia.

  • Platelet or whole blood transfusion, plasmapheresis, or use of any other rescue medications within 14 days before first ianalumab infusion.

  • Participants with the following conditions at screening:

    • Neutrophils <1000/mm3.
    • Immunoglobulin G (IgG) <5 g/L
  • Treatment with a B-cell depleting therapy (e.g., rituximab) or anti-B-cell Activating Factor of the TNF Family (BAFF) (e.g., belimumab) within 12 weeks prior to the first administration of ianalumab.

  • Immunosuppressant drugs other than corticosteroids within 5 times the elimination half-life of the drug or 14 days before first ianalumab infusion, whichever is longer.

  • Prior splenectomy.

Other protocol-defined inclusion/exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Single-arm

All eligible participants will receive ianalumab at the same dose.

Intravenous infusion, prepared from concentrate solution

Outros nomes:
  • VAY736

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Confirmed response
Prazo: Between Week 1 Day 1 and Week 25 Day 1

Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:

  • Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and
  • New immune thrombocytopenia (ITP) treatment before reaching a confirmed response.
Between Week 1 Day 1 and Week 25 Day 1

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Time to confirmed response
Prazo: From Week 1 Day 1 to Week 25 Day 1

Time from the first administration of ianalumab to the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response as defined by the primary endpoint.

From Week 1 Day 1 to Week 25 Day 1
Duration of confirmed response
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time from the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:

  • platelet count <30 G/L,
  • start of any rescue or new ITP treatment,
  • death (whatever the cause).
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Complete Response rate at each timepoint
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Response rate at each timepoint
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Stable response at 6 months
Prazo: At 6 months

Percentage of participants with at least 75% of platelet counts collected at month 6 (between study days 121 and 183) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment.

At 6 months
Stable response at 1 year
Prazo: At 1 year

Percentage of participants with at least 66% of platelet counts collected at year 1 (between study days 296 and 379) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment.

At 1 year
Bleeding events according to the Modified World Health Organization (WHO) bleeding scale
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Percentage of participants with bleeding events according to the Modified World Health Organization (WHO) bleeding scale
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Number of participants who received rescue treatment
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Number of participants who required rescue treatment

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Percentage of participants who received rescue treatment
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Percentage of participants who required rescue treatment

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in the frequency of CD19+ B-cell counts
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline frequency of CD19+ B-cell counts compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in the absolute number of CD19+ B-cell counts
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from baseline in immunoglobulins
Prazo: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to baseline

From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
Prazo: Up to 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Up to 20 weeks after last dose of ianalumab
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
Prazo: Up to 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Up to 20 weeks after last dose of ianalumab
Ianalumab serum concentrations over time
Prazo: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK: AUC concentrations over time
Prazo: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK parameters: Cmax
Prazo: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Ianalumab serum PK parameters: Tmax
Prazo: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
Confirmed response (CR) in the second course
Prazo: Second course Week 1 Day1 to second course Week 25 Day1

Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:

  • Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and
  • New ITP treatment before reaching a confirmed response.
Second course Week 1 Day1 to second course Week 25 Day1
Time to confirmed response in the second course
Prazo: Second course Week 1 Day 1 to second course Week 25 Day 1

two (or more) platelet assessments meeting the criteria of a confirmed response.

Second course Week 1 Day 1 to second course Week 25 Day 1
Duration of confirmed response in the second course
Prazo: Second course Week 1 Day 1 to second course Week 25 Day 1

Time from the first assessment, in the second course of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:

  • platelet count <30 G/L,
  • start of any rescue or new ITP treatment,
  • death (whatever the cause).
Second course Week 1 Day 1 to second course Week 25 Day 1
Response in the second course
Prazo: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

Second course Week 1 Day 1 to second course Week 25 Day 1
Complete Response in the second course
Prazo: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

Second course Week 1 Day 1 to second course Week 25 Day 1
Bleeding events in the second course according to the Modified World Health Organization (WHO) bleeding scale
Prazo: Second course Week 1 Day 1 to second course Week 25 Day 1

Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

Second course Week 1 Day 1 to second course Week 25 Day 1
Percentage of participants with bleeding events in the retreatment/second courseaccording to the Modified World Health Organization (WHO) bleeding scale
Prazo: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

Second course Week 1 Day 1 to second course Week 25 Day 1
Number of Participants who received rescue treatment after second course
Prazo: Second course Week 1 Day 1 to second course Week 25 Day 1

Number of participants who required rescue treatment

Second course Week 1 Day 1 to second course Week 25 Day 1
Percentage of participants who received rescue treatment after receiving second course
Prazo: Second course Week 1 Day 1 to second course Week 25 Day 1

Percentage of participants who required rescue treatment

Second course Week 1 Day 1 to second course Week 25 Day 1
Titer of anti-ianalumab antibodies in serum (ADA assay) over time for second course
Prazo: Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab

Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab
Change from start of second course in immunoglobulins
Prazo: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to retreatment baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from start of second course in the absolute number of CD19+ B-cell counts
Prazo: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Change from start of second course to end of study in the absolute number of CD19+ B-cell counts
Prazo: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Post-baseline absolute number of CD19+ B-cell counts compared to baseline

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Prazo: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
Ianalumab serum concentrations over time in the second course
Prazo: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course

Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

16 de agosto de 2023

Conclusão Primária (Real)

5 de fevereiro de 2025

Conclusão do estudo (Estimado)

19 de março de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

15 de maio de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de maio de 2023

Primeira postagem (Real)

2 de junho de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever